021-51111890
购物车（）
sales@molnova.cn
Vatalanib free base
CAS No. 212141-54-3
Vatalanib free base ( PTK-787;PTK787;PTK/ZK;CGP-79787;ZK-222584;ZK222584 )
产品货号. M13375 CAS No. 212141-54-3
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥446 | 有现货 |
|
| 5MG | ￥640 | 有现货 |
|
| 10MG | ￥956 | 有现货 |
|
| 25MG | ￥1823 | 有现货 |
|
| 50MG | ￥2608 | 有现货 |
|
| 100MG | ￥3904 | 有现货 |
|
| 500MG | ￥8748 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Vatalanib free base
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
-
产品描述A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ; shows no activity against EGFR, FGFR-1, c-Met, and Tie-2, or c-Src, c-Abl, and PKC-α; blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor with IC50 of 34 nM; inhibits EGF and PDGF-induced angiogenesis in a growth factor implant model (25-100 mg/kg).Ovarian Cancer Phase 1 Discontinued
-
同义词PTK-787;PTK787;PTK/ZK;CGP-79787;ZK-222584;ZK222584
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number212141-54-3
-
分子量346.81
-
分子式C20H15ClN4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1
-
化学全称1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bold G, et al. J Med Chem. 2000 Jun 15;43(12):2310-23.
2. Wood JM, et al. Cancer Res. 2000 Apr 15;60(8):2178-89.
3. Drevs J, et al. Cancer Res. 2000 Sep 1;60(17):4819-24.
4. Hess C, et al. Br J Cancer. 2001 Dec 14;85(12):2010-6.
2. Wood JM, et al. Cancer Res. 2000 Apr 15;60(8):2178-89.
3. Drevs J, et al. Cancer Res. 2000 Sep 1;60(17):4819-24.
4. Hess C, et al. Br J Cancer. 2001 Dec 14;85(12):2010-6.
产品手册
关联产品
-
Linifanib
A potent multi-RTKs inhibitor of members of VEGFR and PDGFR families.
-
Vatalanib
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
-
Cabozantinib
Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
